T-Cell Lymphoblastic Leukemia/lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for T-Cell Lymphoblastic Leukemia/lymphoma

MalaCards integrated aliases for T-Cell Lymphoblastic Leukemia/lymphoma:

Name: T-Cell Lymphoblastic Leukemia/lymphoma 12 15
Leukemia, T-Cell 44 70
T-Cell Leukemia 12 17
Leukemia T-Cell 54


External Ids:

Disease Ontology 12 DOID:715
MeSH 44 D015458
UMLS 70 C0023492

Summaries for T-Cell Lymphoblastic Leukemia/lymphoma

MalaCards based summary : T-Cell Lymphoblastic Leukemia/lymphoma, also known as leukemia, t-cell, is related to adult t-cell leukemia and t-cell acute lymphoblastic leukemia. An important gene associated with T-Cell Lymphoblastic Leukemia/lymphoma is MIR106A (MicroRNA 106a), and among its related pathways/superpathways are PI3K-Akt signaling pathway and NF-kappaB Signaling. The drugs Zidovudine and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and myeloid.

Related Diseases for T-Cell Lymphoblastic Leukemia/lymphoma

Diseases related to T-Cell Lymphoblastic Leukemia/lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 557)
# Related Disease Score Top Affiliating Genes
1 adult t-cell leukemia 33.9 IL2RA IL2 CNTN2
2 t-cell acute lymphoblastic leukemia 33.5 TLX1 TAL1 NOTCH1 LMO2 LCK IL2RA
3 precursor t-cell acute lymphoblastic leukemia 33.1 TLX1 TCL1A TAL1 NOTCH1 LMO2
4 human t-cell leukemia virus type 2 33.1 CREB1 CNTN2
5 leukemia, acute lymphoblastic 33.0 TLX1 TCL1B TCL1A TAL1 NOTCH1 MIR130B
6 human t-cell leukemia virus type 1 32.9 CREB1 CNTN2
7 tropical spastic paraparesis 32.8 IL2RA IL2 CNTN2
8 severe combined immunodeficiency 32.0 NOTCH1 LMO2 LCK IL2RA IL2 ADA
9 leukemia, chronic lymphocytic 31.9 TCL1B TCL1A NOTCH1 MIR143 LCK IL2RA
10 peripheral t-cell lymphoma 31.6 TCL1A NOTCH1 IL2
11 leukemia 31.6 TLX1 TCL1B TCL1A TAL1 NOTCH1 LMO2
12 lymphoma, non-hodgkin, familial 31.5 TCL1A TAL1 NOTCH1 MIR143 LCK IL2RA
13 combined immunodeficiency 31.5 NOTCH1 LMO2 LCK IL2RA IL2 ADA
14 hairy cell leukemia 31.5 IL2RA IL2 ADA
15 prolymphocytic leukemia 31.5 TCL1A IL2RA ADA
16 lymphoma 31.5 TLX1 TCL1B TCL1A TAL1 IL2RA IL2
17 acquired immunodeficiency syndrome 31.5 IL2RA IL2 ADA
18 immune deficiency disease 31.4 LCK IL2RA IL2 CNTN2 ADA
19 lymphoblastic lymphoma 31.4 TLX1 TAL1 NOTCH1 LMO2
20 leukemia, acute myeloid 31.3 TAL1 NOTCH1 MIR130B LMO2 LCK IL2
21 lymphopenia 31.3 LCK IL2RA IL2 ADA
22 diffuse large b-cell lymphoma 31.3 MIR143 MIR106A LMO2 CCND3
23 hematologic cancer 31.0 NOTCH1 MIR143 MIR106A IL2RA IL2
24 mantle cell lymphoma 31.0 TCL1A NOTCH1 GAS5 CCND3
25 t-cell adult acute lymphocytic leukemia 31.0 IL2RA IL2 CREB1 CNTN2
26 pulmonary tuberculosis 30.8 IL2RA IL2 ADA
27 tetanus 30.7 IL2RA IL2 CREB1
28 htlv-1 associated myelopathy/tropical spastic paraparesis 11.4
29 myelopathy, htlv-1-associated 11.3
30 t-cell prolymphocytic leukemia 11.3
31 pediatric t-cell leukemia 11.3
32 human t-cell leukemia virus type 3 11.3
33 n syndrome 11.1
34 retrovirus-associated myelopathy 11.1
35 spastic paraparesis 11.0
36 human immunodeficiency virus type 1 10.8
37 mycosis fungoides 10.7
38 cutaneous t cell lymphoma 10.6
39 lymphoproliferative syndrome 10.6
40 graft-versus-host disease 10.6
41 b-cell lymphoma 10.6
42 splenic diffuse red pulp small b-cell lymphoma 10.6 NOTCH1 CCND3
43 severe combined immunodeficiency, x-linked 10.6 LMO2 IL2RA IL2 ADA
44 pleural tuberculosis 10.6 IL2RA IL2 ADA
45 splenic manifestation of leukemia 10.5 TCL1B TCL1A
46 strongyloidiasis 10.5
47 kidney cancer 10.5 MIR20B MIR106A IL2 GAS5
48 uveitis 10.5
49 exanthem 10.5
50 splenomegaly 10.5

Graphical network of the top 20 diseases related to T-Cell Lymphoblastic Leukemia/lymphoma:

Diseases related to T-Cell Lymphoblastic Leukemia/lymphoma

Symptoms & Phenotypes for T-Cell Lymphoblastic Leukemia/lymphoma

Drugs & Therapeutics for T-Cell Lymphoblastic Leukemia/lymphoma

Drugs for T-Cell Lymphoblastic Leukemia/lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 245)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Zidovudine Approved Phase 4 30516-87-1 35370
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Daclizumab Investigational, Withdrawn Phase 4 152923-56-3
5 Reverse Transcriptase Inhibitors Phase 4
6 Anti-Retroviral Agents Phase 4
7 interferons Phase 4
8 Interferon alpha-2 Phase 4
9 Interferon-alpha Phase 4
10 Anti-HIV Agents Phase 4
11 Neurotransmitter Agents Phase 4
12 Psychotropic Drugs Phase 4
13 Anticonvulsants Phase 4
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
Dexrazoxane Approved, Withdrawn Phase 3 24584-09-6 71384
Azathioprine Approved Phase 3 446-86-6 2265
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
Lenograstim Approved, Investigational Phase 3 135968-09-1
Etoposide Approved Phase 3 33419-42-0 36462
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
Pegaspargase Approved, Investigational Phase 3 130167-69-0
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
Mercaptopurine Approved Phase 3 50-44-2 667490
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Bortezomib Approved, Investigational Phase 3 179324-69-7 93860 387447
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
Daunorubicin Approved Phase 3 20830-81-3 30323
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
leucovorin Approved Phase 3 58-05-9 6006
Ichthammol Approved Phase 3 8029-68-3
Thioguanine Approved Phase 3 154-42-7 2723601
Ifosfamide Approved Phase 3 3778-73-2 3690
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
Aclarubicin Investigational Phase 3 57576-44-0 451415
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
Cortisone Experimental Phase 3 53-06-5 222786

Interventional clinical trials:

(show top 50) (show all 186)
# Name Status NCT ID Phase Drugs
1 HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
2 HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens Completed NCT03226119 Phase 4
3 Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b Terminated NCT00854581 Phase 4 Valproic Acid;Zidovudine
4 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma Unknown status NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
5 Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801. Completed NCT00145002 Phase 3 VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis;biweekly-CHOP with G-CSF and intrathecal prophylaxis
6 A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients Recruiting NCT04446130 Phase 3 Decitabine combined with HAAG Regimen
7 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
8 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones Recruiting NCT03007147 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Dexrazoxane Hydrochloride;Doxorubicin;Etoposide;Ifosfamide;Imatinib Mesylate;Leucovorin Calcium;Mercaptopurine;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisolone;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
9 Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
10 A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) Active, not recruiting NCT00557193 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Etoposide;Lestaurtinib;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
11 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) Active, not recruiting NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine;Vincristine Sulfate
12 Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia Unknown status NCT03613428 Phase 1, Phase 2 Ruxolitinib;Vincristine;Prednisone
13 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
14 Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia Completed NCT00061048 Phase 2
15 A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use Completed NCT00095381 Phase 2 forodesine hydrochloride (BCX-1777)
16 Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma (Untreated Primary Disease) Completed NCT01173887 Phase 2 VCAP/AMP/VECP(mLSG15)
17 Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma Completed NCT02631746 Phase 2
18 Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma Completed NCT00920790 Phase 2
19 Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Completed NCT01626664 Phase 2 Pralatrexate;gemcitabine plus oxaliplatin;DHAP
20 Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Completed NCT01378871 Phase 2 IMTOX-25
21 A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma Completed NCT01274533 Phase 2 Lenalidomide
22 A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma Completed NCT01724177 Phase 2 Lenalidomide
23 A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia Completed NCT00001941 Phase 1, Phase 2
24 Phase I/II Study of RAD001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma Completed NCT00081874 Phase 1, Phase 2 RAD001
25 Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma Completed NCT01000285 Phase 1, Phase 2 Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
26 German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
27 A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
28 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
29 Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma Completed NCT00082888 Phase 2 Tipifarnib
30 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
31 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
32 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
33 A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
34 Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma Completed NCT00041327 Phase 2 Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine
35 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
36 Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
37 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
38 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
39 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
40 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
41 A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL) Completed NCT00005080 Phase 2 nelarabine
42 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
43 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
44 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
45 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
46 A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma Completed NCT00611208 Phase 2
47 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
48 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
49 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
50 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib

Search NIH Clinical Center for T-Cell Lymphoblastic Leukemia/lymphoma

Cochrane evidence based reviews: leukemia, t-cell

Genetic Tests for T-Cell Lymphoblastic Leukemia/lymphoma

Anatomical Context for T-Cell Lymphoblastic Leukemia/lymphoma

MalaCards organs/tissues related to T-Cell Lymphoblastic Leukemia/lymphoma:

T Cells, Skin, Myeloid, Bone Marrow, Endothelial, B Cells, Breast

Publications for T-Cell Lymphoblastic Leukemia/lymphoma

Articles related to T-Cell Lymphoblastic Leukemia/lymphoma:

(show top 50) (show all 8997)
# Title Authors PMID Year
Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. 47 61
19464056 2009
Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. 47 61
18974142 2008
Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. 47 61
17575136 2007
Transactivation of human osteopontin promoter by human T-cell leukemia virus type 1-encoded Tax protein. 61 54
19767100 2010
Cyclic AMP response element-binding protein is implicated in IL-6 production from arthritic synovial cells. 54 61
19921094 2010
Molecular approach to human leukemia: isolation and characterization of the first human retrovirus HTLV-1 and its impact on tumorigenesis in adult T-cell leukemia. 61 54
20154469 2010
Tax unleashed: fulminant Tax-positive Adult T-cell Leukemia/Lymphoma after failed allogeneic stem cell transplantation. 54 61
19836302 2009
Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1. 54 61
19587703 2009
Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. 54 61
19564891 2009
Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. 61 54
19561642 2009
Transcriptional activation of the interleukin-21 gene and its receptor gene by human T-cell leukemia virus type 1 Tax in human T-cells. 54 61
19617351 2009
Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia. 61 54
19487290 2009
Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect. 61 54
19555512 2009
Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. 61 54
19461887 2009
Double minute chromosomes containing MYB gene and NUP214-ABL1 fusion gene in T-cell leukemia detected by single nucleotide polymorphism DNA microarray and fluorescence in situ hybridization. 61 54
18799215 2009
Acetylation of the human T-cell leukemia virus type 1 Tax oncoprotein by p300 promotes activation of the NF-kappaB pathway. 61 54
19200568 2009
Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. 54 61
19147787 2009
HTLV-1 Tax is a critical lipid raft modulator that hijacks IkappaB kinases to the microdomains for persistent activation of NF-kappaB. 54 61
19129196 2009
T cell leukemia/lymphoma 1 and galectin-1 regulate survival/cell death pathways in human naive and IgM+ memory B cells through altering balances in Bcl-2 family proteins. 54 61
19155496 2009
Rev and Rex proteins of human complex retroviruses function with the MMTV Rem-responsive element. 54 61
19192308 2009
Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. 61 54
19352436 2009
The proto-oncogene Bcl3, induced by Tax, represses Tax-mediated transcription via p300 displacement from the human T-cell leukemia virus type 1 promoter. 61 54
18815299 2008
Ikaros regulates Notch target gene expression in developing thymocytes. 54 61
18941217 2008
(-)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase. 54 61
18687687 2008
Human T-cell leukemia virus type 1 Tax modulates interferon-alpha signal transduction through competitive usage of the coactivator CBP/p300. 54 61
18678383 2008
Foxp3 expression on normal and leukemic CD4+CD25+ T cells implicated in human T-cell leukemia virus type-1 is inconsistent with Treg cells. 61 54
18510697 2008
An interaction between the human T cell leukemia virus type 1 basic leucine zipper factor (HBZ) and the KIX domain of p300/CBP contributes to the down-regulation of tax-dependent viral transcription by HBZ. 54 61
18599479 2008
Role of human T-cell leukemia virus type I Tax in expression of the human telomerase reverse transcriptase (hTERT) gene in human T-cells. 54 61
18422743 2008
In vitro activation of the IkappaB kinase complex by human T-cell leukemia virus type-1 Tax. 61 54
18223255 2008
The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. 61 54
18246070 2008
The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. 61 54
18227842 2008
The human T-cell leukemia virus type 1 tax protein confers CBP/p300 recruitment and transcriptional activation properties to phosphorylated CREB. 54 61
18070920 2008
Evaluation and validation of housekeeping genes in response to ionizing radiation and chemical exposure for normalizing RNA expression in real-time PCR. 61 54
17904413 2008
Tax-inducible production of CC chemokine ligand 22 by human T cell leukemia virus type 1 (HTLV-1)-infected T cells promotes preferential transmission of HTLV-1 to CCR4-expressing CD4+ T cells. 54 61
18178833 2008
Regulation of telomerase and telomeres: human tumor viruses take control. 61 54
18182620 2008
Activation of the human T-cell leukemia virus type 1 long terminal repeat by the ternary complex factor Elk-1. 54 61
17898074 2007
The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways. 61 54
17846228 2007
Decontamination of leukemic cells and enrichment of germ cells from testicular samples from rats with Roser's T-cell leukemia by flow cytometric sorting. 61 54
18042634 2007
Cooperation of NF-kappaB2/p100 activation and the PDZ domain binding motif signal in human T-cell leukemia virus type 1 (HTLV-1) Tax1 but not HTLV-2 Tax2 is crucial for interleukin-2-independent growth transformation of a T-cell line. 54 61
17715223 2007
Targeting autophagic regulation of NFkappaB in HTLV-I transformed cells by geldanamycin: implications for therapeutic interventions. 61 54
17671417 2007
Notch and Ikaros: not only converging players in T cell leukemia. 61 54
18032925 2007
Neurotropin demonstrates cytoprotective effects in lung cells through the induction of thioredoxin-1. 54 61
17585112 2007
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. 54 61
17873882 2007
Human T-cell leukemia virus type 1 (HTLV-1) p12I down-modulates ICAM-1 and -2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells. 61 54
17609265 2007
BCL3 acts as a negative regulator of transcription from the human T-cell leukemia virus type 1 long terminal repeat through interactions with TORC3. 61 54
17644518 2007
Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. 61 54
17645780 2007
Lipid raft-mediated uptake of cysteine-modified thioredoxin-1: apoptosis enhancement by inhibiting the endogenous thioredoxin-1. 54 61
17627472 2007
Negative regulation of the SH2-homology containing protein-tyrosine phosphatase-1 (SHP-1) P2 promoter by the HTLV-1 Tax oncoprotein. 61 54
17540846 2007
Modulation of dendritic cell maturation and function by the Tax protein of human T cell leukemia virus type 1. 54 61
17442856 2007
Enhanced replication of human T-cell leukemia virus type 1 in T cells from transgenic rats expressing human CRM1 that is regulated in a natural manner. 54 61
17360758 2007

Variations for T-Cell Lymphoblastic Leukemia/lymphoma

Expression for T-Cell Lymphoblastic Leukemia/lymphoma

Search GEO for disease gene expression data for T-Cell Lymphoblastic Leukemia/lymphoma.

Pathways for T-Cell Lymphoblastic Leukemia/lymphoma

GO Terms for T-Cell Lymphoblastic Leukemia/lymphoma

Cellular components related to T-Cell Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 MIR92A2 MIR20B MIR19B2 MIR143 MIR130B MIR106A
2 extracellular vesicle GO:1903561 8.92 MIR92A2 MIR20B MIR19B2 MIR106A

Biological processes related to T-Cell Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.8 NOTCH1 MIR92A2 MIR19B2 CREB1
2 gene silencing by miRNA GO:0035195 9.73 MIR92A2 MIR20B MIR19B2 MIR143 MIR130B MIR106A
3 regulation of cell proliferation GO:0042127 9.67 TAL1 NOTCH1 LCK CCND3
4 miRNA mediated inhibition of translation GO:0035278 9.63 MIR92A2 MIR19B2 MIR106A
5 regulation of regulatory T cell differentiation GO:0045589 9.48 IL2RA IL2
6 negative regulation of inflammatory response GO:0050728 9.46 MIR92A2 IL2RA IL2 ADA
7 positive regulation of T cell receptor signaling pathway GO:0050862 9.43 LCK ADA
8 interleukin-2-mediated signaling pathway GO:0038110 9.4 IL2RA IL2
9 negative regulation of lymphocyte proliferation GO:0050672 9.32 IL2RA IL2
10 regulation of T cell homeostatic proliferation GO:0046013 8.96 IL2RA IL2
11 positive regulation of T cell differentiation GO:0045582 8.8 IL2RA IL2 ADA

Molecular functions related to T-Cell Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.26 MIR20B MIR143 MIR130B MIR106A
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR92A2 MIR20B MIR19B2 MIR143 MIR130B MIR106A

Sources for T-Cell Lymphoblastic Leukemia/lymphoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....